487-79-6
487-79-6
Chemical Structure
Kainic acid
- CAS No.: 487-79-6
- Formula:C10H15NO4
- Molecular Weight:213.23
IUPAC Name: (2S,3S,4S)-3-(carboxymethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylic acid
InChIKey: VLSMHEGGTFMBBZ-OOZYFLPDSA-N
SMILES: O=C(O)C[C@@H]1[C@@H](C(O)=O)NC[C@@H]1C(C)=C
Biological Activity: Kainic acid is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid induces seizures[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Kainic acid | 99.95% | Kainic acid is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid induces seizures. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Kainic acid (Standard) | ≥98% | Kainic acid (Standard) is the analytical standard of Kainic acid (HY-N2309). This product is intended for research and analytical applications. Kainic acid is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid induces seizures. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dihydrokainic acid | 99.0% | Dihydrokainic acid is a glutamate transporters (especially GLT1) inhibitor. Dihydrokainic acid targets GLT1 with high affinity, effectively inhibiting its transport function. Dihydrokainic acid exerts its effect by inhibiting the uptake of glutamate, leading to an increase in extracellular glutamate concentration, thereby affecting neuronal excitability and neurotransmission. Dihydrokainic acid is mainly applied in the field of neuroscience for research on glutamate-related neural functions, epilepsy, learning, and memory. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
trans-4-Carboxy-L-proline | 99.9% | Trans-4-Carboxy-L-prolineis a selective glutamate transporter inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MPDC | MPDC is a potent and competitive inhibitor of the Na+-dependent high-affinity glutamate transporter in forebrain synaptosomes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
rel-ACPT-I | 99.0% | rel-ACPT-I is an agonist of group III mGluRs with diverse biological activities including neuroprotective, anticonvulsant, and anxiolytic-like effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ACPT-II | ACPT-II is an antagonist of group III mGluRs with diverse biological activities including neuroprotective, anticonvulsant, and anxiolytic-like effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(2R,4R)-APDC | (2R,4R)-APDC is a group II metabotropic glutamate receptor (mGluR) agonist. (2R,4R)-APDC affects cell proliferation by inhibiting glutamate release, enhancing motor responses produced by D1 receptor activation, or reducing brain-derived neurotrophic factor (BDNF) levels. (2R,4R)-APDC can be used in the study of epilepsy and other neurological diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-LY395756 | (±)-LY395756 is an agonist of mGlu2 receptor and an antagonist of mGlu3 receptor. (±)-LY395756 can distinguish the native mGlu2 and mGlu3 receptors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LY 221501 | LY 221501 is an active compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
cis-Piperidine-2,3-dicarboxylic acid | 95.0% | Cis-piperidine-2,3-dicarboxylic acid is a non-specific antagonist of NMDA, AMPA and kainate ionotropic receptors and a partial agonist for NMDA receptors. Cis-piperidine-2,3-dicarboxylic acid can be used in blocking general excitatory synaptic transmissions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LBG30300 | LBG30300 is a subtype-selective mGlu2 receptor agonist EC50 0.6 nM. LBG30300 is blood-brain barrier permeable. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Cincioğlu-Palabiyik M, et al. Chronic levetiracetam decreases hippocampal and testicular aromatase expression in normal but not kainic acid-induced experimental model of acute seizures in rats. Neuroreport. 2017 Sep 27;28(14):903-909. [Content Brief]
- [2]. Wang Q, et al. Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol. 2005;31(1-3):3-16. [Content Brief]
